Bookmark and Share
Glycine (CID 750) - Compound BioActivity Data
.
Filters: All Data » Literature      
Filter selected
BioActivity Outcomes:
Active(24)
 
 
Inactive(3)
 
 
Inconclusive(10)
 
 
Unspecified(54)
 
 
Top Targets:
p450(6)
 
 
MFS(4)
 
 
 
Neur chan LBD(3)
 
 
 
SLC6sbd GAT3(3)
 
 
SLC6sbd GAT1(2)
 
 
BioAssay Types:
Literature(91)
 
 
 
 
 
BioActivity Types:
IC50(20)
 
 
 
 
EC50(8)
 
 
 
 
Ki(3)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 91    Data Row: 91   Total Pages: 2   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103204298]
EC50 0.068In vitro concentration eliciting half-maximal effect on [3H]-MK 801 radioligand binding to NMDA receptor [AID145252, Type: Literature]
View
2
[SID103204298]
IC50 0.086Tested for binding affinity against NMDA receptor, from rat synaptic membrane, using [3H]glycine as the radioligand. [AID143072, Type: Literature]
View
3
[SID103204298]
EC50 0.096Effective concentration against NR1/NR2D receptor [AID146064, Type: Literature]
View
4
[SID103204298]
Ki 0.12589Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane [AID430782, Type: Literature]
View
5
[SID103204298]
EC50 0.15Effective concentration against NR1/NR2C receptor [AID146062, Type: Literature]
View
6
[SID103204298]
Ki 0.17Affinity for the glycine binding site of NMDA receptor by inhibition of [3H]5,7-dichlorokynurenic acid ([3H]DCKA) binding to rat brain synaptic membrane [AID143084, Type: Literature]
View
7
[SID103204298]
EC50 0.19Effective concentration against NR1/NR2B receptor [AID146060, Type: Literature]
View
8
[SID103204298]
EC50 0.2Compound was evaluated for in vitro inhibition of [3H]TCP at NMDA receptor [AID144825, Type: Literature]
View
9
[SID103204298]
IC50 0.2In vitro inhibition of [3H]glycine at NMDA receptor [AID145260, Type: Literature]
View
10
[SID103204298]
IC50 0.223Inhibition of rat glutamate receptor [AID566258, Type: Literature]
View
11
[SID103204298]
IC50 0.25In vitro inhibitory activity to inhibit [3H]glycine binding to NMDA receptor [AID143065, Type: Literature]
View
12
[SID103204298]
IC50 0.69Binding affinity against glycine binding site associated with N-methyl-D-aspartate glutamate receptor of rat synaptic plasma membrane(SPM) determined using [3H]glycine as radioligand. [AID144598, Type: Literature]
View
13
[SID103204298]
EC50 0.84Effective concentration against NR1/NR2A receptor [AID146058, Type: Literature]
View
14
[SID103204298]
IC50 6Inhibition of binding of [3H]strychnine to glycine receptor in rat [AID143467, Type: Literature]
View
15
[SID103204298]
IC50 6.2Inhibitory concentration required to inhibit [3H]strychnine binding to N-methyl-D-aspartate glutamate receptor 1 [AID143614, Type: Literature]
View
16
[SID103204298]
IC50 15.8Displacement of [3H]strychnine from strychnine-sensitive glycine receptor in rat spinal cord [AID270051, Type: Literature]
View
17
[SID103204298]
IC50 15.8Displacement of [3H]strychnine from glycine receptor in rat spinal cord synaptosomal membranes [AID286349, Type: Literature]
View
18
[SID103204298]
Binding affinity to 30 mM pyridoxal-5'-phosphate assessed as formation of PLP-aldimine by ESI-MS analysis [AID443653, Type: Literature]
View
19
[SID103204298]
Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
20
[SID103204298]
Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
21
[SID103204298]
Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
22
[SID103204298]
Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
23
[SID103204298]
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
24
[SID103204298]
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins [AID678717, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
25
[SID103204298]
EC50 500Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin [AID51033, Type: Literature]
View
26
[SID103204298]
IC50 1348.96Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells [AID595475, Type: Literature]Sodium- and chloride-dependent GABA transporter 3 [gi:341942004]
View
27
[SID103204298]
IC50 2238.72Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells [AID595474, Type: Literature]Sodium- and chloride-dependent GABA transporter 2 [gi:400623]
View
28
[SID103204298]
IC50 3090.3Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells [AID595476, Type: Literature]
View
29
[SID103204298]
Ki 5100Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting [AID630741, Type: Literature]Proton-coupled amino acid transporter 1 [gi:51316800]
View
30
[SID103204298]
IC50 50000Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay [AID695876, Type: Literature]
View
31
[SID103204298]
IC50 50000Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay [AID695877, Type: Literature]
View
32
[SID103204298]
Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM [AID631077, Type: Literature]Sodium- and chloride-dependent GABA transporter 1 [gi:47117844]
View
33
[SID103204298]
Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM [AID631078, Type: Literature]Sodium- and chloride-dependent GABA transporter 2 [gi:400623]
View
34
[SID103204298]
Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM [AID631079, Type: Literature]Sodium- and chloride-dependent GABA transporter 3 [gi:341942004]
View
35
[SID103204298]
Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM [AID631080, Type: Literature]Sodium- and chloride-dependent GABA transporter 3 [gi:341942004]
View
36
[SID103204298]
Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 10 mM [AID595481, Type: Literature]Sodium- and chloride-dependent GABA transporter 1 [gi:47117844]
View
37
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia [AID625279, Type: Literature]
View
38
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis [AID625280, Type: Literature]
View
39
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis [AID625281, Type: Literature]
View
40
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis [AID625282, Type: Literature]
View
41
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests [AID625283, Type: Literature]
View
42
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure [AID625284, Type: Literature]
View
43
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis [AID625285, Type: Literature]
View
44
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis [AID625286, Type: Literature]
View
45
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly [AID625287, Type: Literature]
View
46
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice [AID625288, Type: Literature]
View
47
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease [AID625289, Type: Literature]
View
48
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty [AID625290, Type: Literature]
View
49
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal [AID625291, Type: Literature]
View
50
[SID103204298]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score [AID625292, Type: Literature]
View